WallStreetZenWallStreetZen

NASDAQ: GYRE
Gyre Therapeutics Inc Stock

$20.77+2.49 (+13.62%)
Updated Dec 8, 2023
GYRE Price
$20.77
Fair Value Price
N/A
Market Cap
$52.59M
52 Week Low
$2.83
52 Week High
$27.39
P/E
-1x
P/B
14.95x
P/S
N/A
PEG
N/A
Dividend Yield
16.18%
Revenue
$0.00
Earnings
-$44.24M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.83
Operating Cash Flow
-$13M
Beta
1.17
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GYRE Overview

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GYRE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GYRE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GYRE is poor value based on its book value relative to its share price (14.95x), compared to the US Biotechnology industry average (5.42x)
P/B vs Industry Valuation
GYRE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more GYRE due diligence checks available for Premium users.

Be the first to know about important GYRE news, forecast changes, insider trades & much more!

GYRE News

Valuation

GYRE fair value

Fair Value of GYRE stock based on Discounted Cash Flow (DCF)
Price
$20.77
Fair Value
$0.72
Overvalued by
2,766.73%
GYRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GYRE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1x
Industry
11.7x
Market
31.32x

GYRE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
14.95x
Industry
5.42x
GYRE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GYRE's financial health

Profit margin

Revenue
$0.0
Net Income
-$1.6M
Profit Margin
0%
GYRE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$10.0M
Liabilities
$6.4M
Debt to equity
1.83
GYRE's short-term assets ($5.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GYRE's short-term assets ($5.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GYRE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GYRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.2M
Investing
$0.0
Financing
-$1.5M
GYRE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GYRE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
GYRE$52.59M+13.62%-1.00x14.95x
CRVO$52.49M+4.99%-1.35x5.48x
IMUX$53.27M-4.07%-0.36x1.10x
LGVN$53.92M-4.22%-2.32x8.13x
YS$51.09M+0.92%N/A0.08x

Gyre Therapeutics Stock FAQ

What is Gyre Therapeutics's quote symbol?

(NASDAQ: GYRE) Gyre Therapeutics trades on the NASDAQ under the ticker symbol GYRE. Gyre Therapeutics stock quotes can also be displayed as NASDAQ: GYRE.

If you're new to stock investing, here's how to buy Gyre Therapeutics stock.

What is the 52 week high and low for Gyre Therapeutics (NASDAQ: GYRE)?

(NASDAQ: GYRE) Gyre Therapeutics's 52-week high was $27.39, and its 52-week low was $2.83. It is currently -24.17% from its 52-week high and 633.66% from its 52-week low.

How much is Gyre Therapeutics stock worth today?

(NASDAQ: GYRE) Gyre Therapeutics currently has 2,531,876 outstanding shares. With Gyre Therapeutics stock trading at $20.77 per share, the total value of Gyre Therapeutics stock (market capitalization) is $52.59M.

Gyre Therapeutics stock was originally listed at a price of $13,639.50 in Apr 12, 2006. If you had invested in Gyre Therapeutics stock at $13,639.50, your return over the last 17 years would have been -99.85%, for an annualized return of -31.72% (not including any dividends or dividend reinvestments).

How much is Gyre Therapeutics's stock price per share?

(NASDAQ: GYRE) Gyre Therapeutics stock price per share is $20.77 today (as of Dec 8, 2023).

What is Gyre Therapeutics's Market Cap?

(NASDAQ: GYRE) Gyre Therapeutics's market cap is $52.59M, as of Dec 11, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Gyre Therapeutics's market cap is calculated by multiplying GYRE's current stock price of $20.77 by GYRE's total outstanding shares of 2,531,876.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.